Trial · NCT02638597
Gemfibrozil for Nicotine Smoking Cessation
NCT02638597, Phase 2, Completed, University of Texas Southwestern Medical Center; results first posted 2019-02-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Gemfibrozil for Nicotine Smoking Cessation. Trials, record NCT02638597. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02638597
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Gemfibrozil for Nicotine Smoking Cessation
- NCT number
- NCT02638597
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 16 participants, actual
- Lead sponsor
- University of Texas Southwestern Medical Center
- Conditions
- Smoking Cessation
- Interventions
- Gemfibrozil, smoking cessation counseling
- First posted
- 2015-12-23
- Last updated
- 2019-02-01
- Results first posted
- 2019-02-01
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Exhaled Carbon Monoxide (CO) | 8 weeks after target quit date | Exhaled carbon monoxide change from baseline to last available visit. |
| Secondary | Heaviness of Smoking Index | 8 weeks after target quit date | The outcome measure was Heaviness of Smoking Index at exit. The Heaviness of Smoking Index is a two-item scale, with scores on each item rated on a 1-4 likert scale. The total score of the measure ranges from 2-8, with higher scores indicating worse outcome. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Exhaled Carbon Monoxide (CO) | 8 weeks after target quit date | Parts p/million | MEAN | |
| SECONDARY | Heaviness of Smoking Index | 8 weeks after target quit date | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Exhaled Carbon Monoxide (CO) | Gemfibrozil | 10.88 | Standard Deviation 12.63 | Parts p/million | |
| Exhaled Carbon Monoxide (CO) | Waitlist | 21.63 | Standard Deviation 22.04 | Parts p/million | |
| Heaviness of Smoking Index | Waitlist | 1.25 | Standard Deviation 1.04 | score on a scale | |
| Heaviness of Smoking Index | Gemfibrozil | 1.63 | Standard Deviation 1.30 | score on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Waitlist | 8 | |
| Overall Study | STARTED | Gemfibrozil | 8 | |
| Overall Study | COMPLETED | Waitlist | 4 | |
| Overall Study | COMPLETED | Gemfibrozil | 3 | |
| Overall Study | NOT COMPLETED | Waitlist | 4 | |
| Overall Study | NOT COMPLETED | Gemfibrozil | 5 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Arm bruising | Skin and subcutaneous tissue disorders | Gemfibrozil | 0 | 8 | 0 |
| other | Arm bruising | Skin and subcutaneous tissue disorders | Waitlist | 1 | 8 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Gemfibrozil | 1 | 8 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Waitlist | 0 | 8 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Gemfibrozil | ||
| Total, all-cause mortality | Waitlist | ||
| Total, other adverse events | Gemfibrozil | 1 | 8 |
| Total, other adverse events | Waitlist | 1 | 8 |
| Total, serious adverse events | Gemfibrozil | 0 | 8 |
| Total, serious adverse events | Waitlist | 0 | 8 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Gemfibrozil vs Waitlist: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02638597
GET https://conductscience.org/api/trials/v1/NCT02638597/registered